Clinical Trial Update: A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. [Phase 3]

View source ↗

Summary

Phase 3 study of A-101 Solution 40% in seborrheic keratosis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seborrheic Keratosis

Drugs mentioned

• A-101 Solution 40%

Snippet

Sponsor: Aclaris Therapeutics, Inc. | Conditions: Seborrheic Keratosis | Phase 3 | Status: COMPLETED | Results posted: 2017-11-13